| Sourced from 4 independent sources (5 reports) · no points in dispute |
Marijuana Herald, StratCann, The Globe and Mail, and Mirage News
Most key facts are confirmed by more than one independent source; a few details come from a single outlet.
8 key facts · 7 corroborated · none disputed
Why some reports were counted once
The Globe and Mail and Head Topics — the same Canadian Press report, counted once.
When several outlets publish the identical article — most often because they all ran the same wire story from an agency like The Canadian Press — we count it as one source, not several. That keeps our source count a measure of independent reporting, not how widely a single story was syndicated.
This summary is compiled from the independent sources listed above.
Federal Health Minister Marjorie Michel is putting new money behind one of the most persistent questions since cannabis legalization: what does it do to the brain, and how does that change over a lifetime?
Michel announced a $24 million Government of Canada investment through the Canadian Institutes of Health Research to establish the Canadian Cannabis and Brain Health Consortium, Canada’s first national cannabis and brain health research consortium.
Canada’s first national consortium
The new consortium will bring together 10 research teams from across Canada to study how cannabis affects brain health across the lifespan.
“Good health policy starts with strong evidence,” Michel said. “This $24 million investment will bring together researchers from across the country to advance our understanding of how cannabis affects brain health and generate knowledge that helps improve care, inform policy and supports the health of Canadians.”
The announcement lands in a country where cannabis is no longer a niche public-health issue. More than one in three Canadian adults reported using cannabis in 2025, after Canada legalized non-medical cannabis use in 2018.
That scale helps explain the federal focus. The consortium is designed not to start from a fixed conclusion, but to examine cannabis as both a possible therapeutic tool and a source of potential harm.
Benefits and harms under study
The research will look at cannabis through several different health lenses, including epilepsy, post-traumatic stress disorder, sleep, mental health, pregnancy and brain development in youth.
That breadth matters because cannabis use can mean very different things depending on the person, the reason for use and the stage of life. A youth’s brain development, a pregnant person’s health, sleep concerns, mental health symptoms and neurological conditions such as epilepsy raise different questions for researchers and clinicians.
Dr. Patricia Conrod said the work is meant to move Canadian evidence forward on both sides of the ledger.
“It’s bringing together Canada’s top brain health and cannabis researchers in order to really bring us to another place in terms of understanding the potential benefits and the potential harms of cannabis use for our population,” she said.
Building a shared data resource
Beyond individual studies, the initiative will create a shared research data resource for Canadian cannabis and brain-health studies.
That shared resource is a central piece of the federal investment. Rather than leaving teams to build separate pools of evidence in isolation, the consortium is intended to support a broader national research base that other Canadian researchers can use.
According to The Globe and Mail, researchers plan to recruit more than 3,000 people of all ages and collect data about brain function, mental health and substance use. The newspaper reported that Conrod said the data will be open for other Canadian researchers to use in their own cannabis studies.
Evidence for care and policy
The consortium’s mandate sits at the intersection of health care, public policy and everyday Canadian choices. Cannabis is widely used, but the federal investment signals that major evidence gaps remain around how it affects brain health at different points in life.
The research teams will examine therapeutic potential alongside possible harms, a framing that avoids reducing the debate to simple claims for or against cannabis. For patients, clinicians and policymakers, the goal is evidence that can better inform decisions about use, prevention, care and regulation.
“As cannabis use and products continue to evolve, so must our understanding of their effects on health,” Conrod said. “The Canadian Cannabis and Brain Health Consortium will help researchers build a stronger understanding of how cannabis affects people’s health at every stage of life, generating knowledge that can guide prevention, care and evidence-informed policies for years to come.”
For Canadians, the practical stakes are clear: cannabis has been legal for non-medical use since 2018, and a large share of adults report using it. The new national consortium is meant to help answer what that means for the brain, from youth development to later-life health, and from possible treatment uses to risks that remain poorly understood.
Reader-funded. No ads. No paywall.
The Canada Report is independent, reader-funded Canadian news — no advertisers, nothing behind a paywall, kept free for everyone. If you value it, you can help keep it that way.
Support The Canada Report →
